Loading...
Loading...
Browse all stories on DeepNewz
VisitInsitro and Eli Lilly Announce AI Deal to Accelerate Genetic Medicine Development
Oct 9, 2024, 03:30 PM
Insitro has announced a collaboration with Eli Lilly and Company to accelerate the development of Insitro's genetic medicine using Lilly's proprietary GalNAc delivery technology and expertise in biologics design. The partnership aims to bring Insitro's discoveries to the clinic, with the first drug expected to enter clinical trials by 2026. Insitro retains full global rights to its discoveries, while Lilly is eligible to receive potential benefits from the collaboration. The collaboration also includes an AI deal between Insitro and Eli Lilly.
View original story
Markets
No • 50%
Yes • 50%
Official announcements or press releases from Eli Lilly or Insitro
No • 50%
Yes • 50%
Financial statements or press releases from Insitro or Eli Lilly
Yes • 50%
No • 50%
Clinical trial registries or press releases from Insitro or Eli Lilly
Cardiovascular • 25%
Other • 25%
Neurology • 25%
Oncology • 25%
Clinical trial registries or press releases from Insitro or Eli Lilly
Other • 25%
Machine Learning • 25%
Deep Learning • 25%
Natural Language Processing • 25%
Scientific publications or press releases from Insitro or Eli Lilly
PMDA (Japan) • 25%
Other • 25%
FDA (USA) • 25%
EMA (Europe) • 25%
Regulatory authority announcements or press releases from Insitro or Eli Lilly